Loading...

We've got a brand new version of Simply Wall St! Try it out

Axsome Therapeutics

Nasdaq:AXSM
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AXSM
Nasdaq
$848M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
AXSM Share Price and Events
7 Day Returns
-3.1%
NasdaqGM:AXSM
-1.8%
US Pharmaceuticals
-1%
US Market
1 Year Returns
970.9%
NasdaqGM:AXSM
-6.6%
US Pharmaceuticals
-0.4%
US Market
AXSM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Axsome Therapeutics (AXSM) -3.1% -0.9% 4.4% 970.9% 224.9% -
US Pharmaceuticals -1.8% -3.5% -3.8% -6.6% 0.6% 10%
US Market -1% -3.3% 0.8% -0.4% 30.4% 37.1%
1 Year Return vs Industry and Market
  • AXSM outperformed the Pharmaceuticals industry which returned -6.6% over the past year.
  • AXSM outperformed the Market in United States of America which returned -0.4% over the past year.
Price Volatility
AXSM
Industry
5yr Volatility vs Market

Value

 Is Axsome Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Axsome Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $24.63.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Axsome Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Axsome Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AXSM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-1.37
NasdaqGM:AXSM Share Price ** NasdaqGM (2019-08-16) in USD $24.63
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 31 Publicly-Listed Pharmaceuticals Companies 18.17x
United States of America Market PE Ratio Median Figure of 3,096 Publicly-Listed Companies 17.26x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Axsome Therapeutics.

NasdaqGM:AXSM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AXSM Share Price ÷ EPS (both in USD)

= 24.63 ÷ -1.37

-17.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Axsome Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Axsome Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Axsome Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:AXSM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
17.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 2.11x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Axsome Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Axsome Therapeutics's assets?
Raw Data
NasdaqGM:AXSM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.71
NasdaqGM:AXSM Share Price * NasdaqGM (2019-08-16) in USD $24.63
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 182 Publicly-Listed Pharmaceuticals Companies 3.06x
United States of America Market PB Ratio Median Figure of 5,273 Publicly-Listed Companies 1.7x
NasdaqGM:AXSM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AXSM Share Price ÷ Book Value per Share (both in USD)

= 24.63 ÷ 0.71

34.82x

* Primary Listing of Axsome Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Axsome Therapeutics is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Axsome Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Axsome Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Axsome Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Axsome Therapeutics expected to grow at an attractive rate?
  • Axsome Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Axsome Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Axsome Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AXSM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AXSM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 17.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AXSM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AXSM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 423 57 40 1
2022-12-31 197 -50 -60 1
2021-12-31 35 -75 -86 1
2020-12-31 11 -49 -49 6
2019-12-31 0 -48 -51 6
NasdaqGM:AXSM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 -34 -42
2019-03-31 -33 -37
2018-12-31 -30 -31
2018-09-30 -27 -29
2018-06-30 -27 -27
2018-03-31 -27 -26
2017-12-31 -26 -29
2017-09-30 -27 -29
2017-06-30 -26 -30
2017-03-31 -24 -29
2016-12-31 -21 -27
2016-09-30 -16 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Axsome Therapeutics's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Axsome Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AXSM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Axsome Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AXSM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.00 1.00 1.00 1.00
2022-12-31 -1.50 -1.50 -1.50 1.00
2021-12-31 -2.20 -2.20 -2.20 1.00
2020-12-31 -1.28 -0.85 -1.72 6.00
2019-12-31 -1.47 -1.38 -1.54 6.00
NasdaqGM:AXSM Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -1.37
2019-03-31 -1.28
2018-12-31 -1.15
2018-09-30 -1.13
2018-06-30 -1.09
2018-03-31 -1.06
2017-12-31 -1.27
2017-09-30 -1.34
2017-06-30 -1.45
2017-03-31 -1.52
2016-12-31 -1.42
2016-09-30 -1.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Axsome Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Axsome Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Axsome Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Axsome Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Axsome Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Axsome Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Axsome Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Axsome Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Axsome Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Axsome Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AXSM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -42.28 9.77 31.58
2019-03-31 -36.80 9.76 26.13
2018-12-31 -30.97 9.35 23.28
2018-09-30 -28.80 9.00 20.62
2018-06-30 -26.95 8.63 19.06
2018-03-31 -25.75 7.93 18.52
2017-12-31 -28.94 7.21 19.75
2017-09-30 -28.84 7.08 20.59
2017-06-30 -29.60 6.89 21.89
2017-03-31 -29.33 6.67 22.18
2016-12-31 -27.20 6.34 20.73
2016-09-30 -23.24 5.47 17.60
2016-06-30 -20.62 4.33 13.56
2016-03-31 -15.94 3.26 9.89
2015-12-31 -12.21 2.42 6.78
2015-09-30 -10.33 2.07 5.92
2015-06-30 -6.01 1.97 5.69
2015-03-31 -6.01 1.71 4.79
2014-12-31 -6.00 1.39 4.10
2013-12-31 -2.17 0.30 1.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Axsome Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Axsome Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Axsome Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Axsome Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Axsome Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Axsome Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Axsome Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Axsome Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Axsome Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Axsome Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Axsome Therapeutics Company Filings, last reported 1 month ago.

NasdaqGM:AXSM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 24.28 19.58 53.75
2019-03-31 17.37 19.35 42.62
2018-12-31 0.94 6.91 13.97
2018-09-30 0.74 7.73 15.22
2018-06-30 7.01 8.47 20.35
2018-03-31 12.59 9.21 26.63
2017-12-31 16.72 9.93 34.02
2017-09-30 16.84 10.09 31.67
2017-06-30 22.75 9.97 37.99
2017-03-31 29.28 9.86 45.02
2016-12-31 21.57 9.74 36.62
2016-09-30 28.18 0.00 33.89
2016-06-30 34.90 0.00 38.75
2016-03-31 41.23 0.00 44.08
2015-12-31 46.44 0.00 48.04
2015-09-30 -11.43 15.14 4.62
2015-06-30 -7.21 10.91 6.41
2015-03-31 -3.20 4.48 2.62
2014-12-31 -3.20 4.48 2.62
2013-12-31 -2.03 3.83 2.09
  • Axsome Therapeutics's level of debt (80.6%) compared to net worth is high (greater than 40%).
  • Axsome Therapeutics had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Axsome Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.
  • Axsome Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 21.4% each year.
X
Financial health checks
We assess Axsome Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Axsome Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Axsome Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Axsome Therapeutics dividends.
If you bought $2,000 of Axsome Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Axsome Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Axsome Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AXSM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2010 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AXSM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Axsome Therapeutics has not reported any payouts.
  • Unable to verify if Axsome Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Axsome Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Axsome Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Axsome Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Axsome Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Axsome Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Axsome Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Herriot Tabuteau
COMPENSATION $1,057,425
AGE 51
TENURE AS CEO 7.6 years
CEO Bio

Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer and Chairman since January 2012. Dr. Tabuteau serves as President at Axsome Therapeutics, Inc. and was its Interim Principal Financial Officer since May 9, 2018 until May 16, 2018. Dr. Tabuteau is also the Founder and Managing Member at Antecip Capital LLC (formerly Versant Capital Management, LLC). He was an Analyst-Medical Products at Montgomery Securities. He began his professional career as an investment banking analyst at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School Medical and his B.A. in molecular biology and biochemistry from Wesleyan University.

CEO Compensation
  • Herriot's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Herriot's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Axsome Therapeutics management team in years:

2.9
Average Tenure
44
Average Age
  • The tenure for the Axsome Therapeutics management team is about average.
Management Team

Herriot Tabuteau

TITLE
Founder
COMPENSATION
$1M
AGE
51
TENURE
7.6 yrs

Nick Pizzie

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$688K
AGE
44
TENURE
1.3 yrs

Mark Jacobson

TITLE
Senior Vice President of Operations & Secretary
AGE
36
TENURE
3.8 yrs

Cedric O'Gorman

TITLE
Senior Vice President of Clinical Development & Medical Affairs
AGE
44
TENURE
1.9 yrs

Joseph Debrah-Afful

TITLE
Director of Finance
Board of Directors Tenure

Average tenure and age of the Axsome Therapeutics board of directors in years:

4.7
Average Tenure
51
Average Age
  • The tenure for the Axsome Therapeutics board of directors is about average.
Board of Directors

Herriot Tabuteau

TITLE
Founder
COMPENSATION
$1M
AGE
51
TENURE
7.6 yrs

Roger Jeffs

TITLE
Lead Director
COMPENSATION
$99K
AGE
57

Mark Saad

TITLE
Director
COMPENSATION
$88K
AGE
49
TENURE
4.7 yrs

Myrtle Potter

TITLE
Director
COMPENSATION
$95K
AGE
61
TENURE
2.2 yrs

Mark Coleman

TITLE
Director
COMPENSATION
$81K
AGE
51
TENURE
4.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Axsome Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Jun 19 Buy Mark Coleman Individual 25. Jun 19 26. Jun 19 16,200 $23.25 $374,280
12. Jun 19 Buy Nick Pizzie Individual 11. Jun 19 11. Jun 19 1,920 $20.80 $39,936
24. May 19 Buy Mark Saad Individual 23. May 19 23. May 19 3,500 $22.33 $78,155
15. May 19 Buy Mark Coleman Individual 13. May 19 13. May 19 4,650 $21.44 $99,696
21. Mar 19 Buy Nick Pizzie Individual 19. Mar 19 19. Mar 19 5,400 $12.69 $67,939
21. Mar 19 Buy Mark Coleman Individual 19. Mar 19 19. Mar 19 5,100 $12.18 $62,118
X
Management checks
We assess Axsome Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Axsome Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Investor Owns Most Of Axsome Therapeutics, Inc. (NASDAQ:AXSM)?

Insider Ownership Of Axsome Therapeutics The definition of company insiders can be subjective, and does vary between jurisdictions. … Shareholders would probably be interested to learn that insiders own shares in Axsome Therapeutics, Inc.. … Private Company Ownership Our data indicates that Private Companies hold 22%, of the company's shares.

Simply Wall St -

Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year?

NasdaqGM:AXSM Recent Insider Trading, June 5th 2019 Axsome Therapeutics is not the only stock insiders are buying. … Axsome Therapeutics Insiders Bought Stock Recently Over the last three months, we've seen significant insider buying at Axsome Therapeutics. … Does Axsome Therapeutics Boast High Insider Ownership?

Simply Wall St -

If You Had Bought Axsome Therapeutics (NASDAQ:AXSM) Stock A Year Ago, You Could Pocket A 410% Gain Today

See our latest analysis for Axsome Therapeutics. … Axsome Therapeutics didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … It seems likely some shareholders believe that Axsome Therapeutics will significantly advance the business plan before too long.

Simply Wall St -

Could The Axsome Therapeutics Inc (NASDAQ:AXSM) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Axsome Therapeutics Inc (NASDAQ:AXSM) have power over the company. … Axsome Therapeutics is a smaller company with a market capitalization of US$93m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Axsome Therapeutics

Simply Wall St -

Are Axsome Therapeutics Inc's (NASDAQ:AXSM) Interest Costs Too High?

Axsome Therapeutics Inc (NASDAQ:AXSM) is a small-cap stock with a market capitalization of US$63.01m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes

Simply Wall St -

Are Axsome Therapeutics Inc's (NASDAQ:AXSM) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Axsome Therapeutics Inc (NASDAQ:AXSM), with a market cap of US$77.06m. … However, an important fact which most ignore is: how financially healthy is the business? … Companies operating in the Pharmaceuticals industry,

Simply Wall St -

Why Axsome Therapeutics Inc's (NASDAQ:AXSM) Ownership Structure Is Important

See our latest analysis for Axsome Therapeutics NasdaqGM:AXSM Ownership_summary Jun 1st 18 Institutional Ownership In AXSM's case, institutional ownership stands at 16.37%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: AXSM's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

What You Must Know About Axsome Therapeutics Inc's (NASDAQ:AXSM) Financial Strength

How does AXSM’s operating cash flow stack up against its debt? … At this stable level of debt, AXSM's cash and short-term investments stands at US$34.02M , ready to deploy into the business. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: At its current level of cash flow coverage, AXSM has room for improvement to better cushion for events which may require debt repayment.

Simply Wall St -

How Much Did Axsome Therapeutics Inc's (NASDAQ:AXSM) CEO Pocket Last Year?

See our latest analysis for Axsome Therapeutics What has AXSM's performance been like? … In the past year, AXSM released negative earnings of -US$28.94M , which is a further decline from prior year's loss of -US$27.20M. … Typically I would use earnings and market cap to account for variations in performance, however, AXSM's negative earnings lower the usefulness of my formula.

Simply Wall St -

Axsome Therapeutics Inc's (NASDAQ:AXSM) Profit Outlook

Many investors are wondering the rate at which AXSM will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for AXSM, its year of breakeven and its implied growth rate. … Working backwards from analyst estimates, it turns out that they expect the company to grow 2.90% year-on-year, on average, which is relatively conservative. … If this rate turns out to be too low, AXSM may become profitable faster than analysts expect.

Simply Wall St -

Company Info

Description

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Details
Name: Axsome Therapeutics, Inc.
AXSM
Exchange: NasdaqGM
Founded: 2012
$847,728,985
34,418,554
Website: http://www.axsome.com
Address: Axsome Therapeutics, Inc.
200 Broadway,
3rd Floor,
New York,
New York, 10038,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AXSM Common Stock Nasdaq Global Market US USD 19. Nov 2015
DB 19X Common Stock Deutsche Boerse AG DE EUR 19. Nov 2015
LSE 0HKF Common Stock London Stock Exchange GB USD 19. Nov 2015
Number of employees
Current staff
Staff numbers
37
Axsome Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/19 00:42
End of day share price update: 2019/08/16 00:00
Last estimates confirmation: 2019/08/09
Last earnings filing: 2019/08/08
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.